Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.

ABSTRACT:

Background

Patients with non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, are at higher risk of cardiovascular disease (CVD) and associated mortality. Therefore, it is important to understand how new therapies for non-alcoholic steatohepatitis (NASH) may impact CVD risk factors in these patients.

Aims

To summarise the effects of drug therapies on lipid and lipoprotein levels in patients with NASH and provide insight into the potential mechanisms for the observed changes.

Methods

PubMed searches of the literature were performed and results were compiled.

Results

Recent clinical trials have highlighted the safety and efficacy of drug candidates for the treatment of NASH. Several agents have shown improvements in the histo

SUBMITTER: Connelly MA 

PROVIDER: S-EPMC7497003 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature